




## Parkinson's Disease Biomarkers

Dear Researcher,

Levels of  $\alpha$ -synuclein monomer and its oligomeric, aggregated and phosphorylated forms are well known to change in Parkinson's Disease. An excellent review by [Parnetti \*et al.\* \(2019\)](#), published in Lancet Neurology, discusses the Biomarker potential of  $\alpha$ -synuclein isoforms and their clinical utility.

Biosensis is addressing the need for reliable and accurate quantification of  $\alpha$ -synuclein by releasing its **NEW Rapid™** ELISA Kit for this important target ([BEK-2216](#)). It represents the first assay in Biosensis' collection of  $\alpha$ -synuclein ELISA kits, with more kits in development!



Accurate quantification of  $\alpha$ -synuclein in human citrate-plasma (A), human serum (B) and CSF (C).



## Our new $\alpha$ -synuclein *Rapid*<sup>™</sup> ELISA Kit features:

- Real validation data on accurate quantification in human blood and CSF
- Low intra- and inter-assay CVs of < 10%
- Complete kit with precise instructions
- Fast (< 4 hours) and reliable assay performance

For more details on our  $\alpha$ -synuclein *Rapid*<sup>™</sup> ELISA Kit, please find our protocol [here](#), or contact us at [biospeak@biosensis.com](mailto:biospeak@biosensis.com).

Good luck with your research,

The Biosensis Team